Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
HIV cure audit launched

On November 5th The European AIDS Treatment Group (EATG) announced the launch of an audit designed to assess current and future levels of investment in research into a cure for HIV. Yet, while there have been significant advances in the prevention and treatment of HIV, there is no cure.

Published
13 November 2014
From
EATG
Restoring and maintaining a high CD4 count possible for vast majority of people living with HIV in France

A large French study has shown that the vast majority of people living with HIV who started treatment since 2000 in a national cohort achieved a CD4

Published
12 November 2014
By
Alain Volny-Anne
The genetics of coping with HIV

We respond to infections in two fundamental ways. One is 'resistance,' where the body attacks the invading pathogen and reduces its numbers. Another, which is much less well understood, is 'tolerance,' where the body tries to minimize the damage done by the pathogen. A study using data from a large Swiss cohort of HIV-infected individuals gives us a glimpse into why some people cope with HIV better than others.

Published
12 November 2014
From
Science Daily
What are the barriers that could stop HIV treatment becoming HIV prevention?

One of the key strategies involved in trying to bring an end to the HIV epidemic is to increase the proportion of HIV-positive people on antiretroviral therapy

Published
12 November 2014
By
Gus Cairns
Researchers See New Avenue For HIV Cure: Endogenization

French scientists believe they have identified the means by which two HIV-positive men have been “spontaneously cured,” and that this insight may carve a new cure pathway.

Published
11 November 2014
From
AIDSmeds.com
Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up

Treatment with a triple antiretroviral combination containing once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina

Published
10 November 2014
By
Alain Volny-Anne
Doravirine works as well as efavirenz with fewer CNS side-effects

Once-daily doravirine (MK-1439), an experimental NNRTI, demonstrated viral suppression similar to that of efavirenz at 48 weeks, and the dose selected for further development was associated with fewer

Published
10 November 2014
By
Liz Highleyman
Scientists see mechanism for spontaneous HIV 'cure'

French scientists claimed Tuesday to have found the genetic mechanism for a "spontaneous cure" in two HIV-infected men, proposing a new strategy for combating AIDS even as other experts urged caution.

Published
10 November 2014
From
AFP / Yahoo News
Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy

Darunavir/ritonavir monotherapy results in a lower rate of viral suppression after 48 weeks when compared to darunavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs), but may

Published
07 November 2014
By
Keith Alcorn
Innovation in fixed-dose combos: HIV/AIDS therapeutics edition

FDC drug development is evolving rapidly as the industry gains experience in manufacturing them and ushering them through the review process. The laws have changed towards a more favorable marketing climate. And finally, it is clear that FDCs are more than a way to improve adherence—though that will always be a prominent consideration. FDCs can shift the standard of care towards a more tolerable, patient-friendly, value-oriented approach to treatment, and in the final analysis, that approach to development bodes well for companies, payers, and most importantly, patients.

Published
07 November 2014
From
BioPharma Dive

Filter by country